- $20.93bn
- $32.87bn
- $14.30bn
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Deals of the day-Mergers and acquisitions
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Brief: Viatris Agrees To Acquire Pacira Biosciences, Advancing Its Innovative Medicines Strategy And Becoming A Leader In Non-Opioid Pain Therapies
Advisory: Incorrect alert on Pacira Biosciences' share movement withdrawn
Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal (updated)
Viatris to acquire Pacira Biosciences in $1.65 billion deal
Mylan asks US court to clear Wegovy generic from Novo patent claims
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
U.S. STOCKS ON THE MOVE-UGI, Chewy, Cognyte Software
Leerink starts Viatris at 'outperform' on improving growth
Roivant's experimental lung disease drug meets goals in mid-stage study (updated)
Roivant's experimental lung disease drug meets goals in mid-stage study
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns (updated)
U.S. STOCKS ON THE MOVE-Braveheart Bio, Paysign, Hertz Global
U.S. STOCKS ON THE MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln International
Viatris Inc. reports results for the quarter ended June 30 - Earnings Summary